Ye Won Jeon

Ye Won Jeon

Auto-generated profile, based on publicly available information

Ye Won Jeon

Department of Surgery, Division of Breast & Thyroid Surgical Oncology, College of Medicine, The Catholic University of Korea, Seoul, Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Acta Biomaterialia
Verified
Journal Article
Open access
HHHee Dong Han
Hee Dong Han
YJYe Won Jeon
Ye Won Jeon
HKHo Jin Kwon
Ho Jin Kwon
HJHat Nim Jeon
Hat Nim Jeon
YBYeongseon Byeon
Yeongseon Byeon
BSByung Cheol Shin
Byung Cheol Shin
Drug delivery using thermosensitive liposomes (TSL) has significant potential for tumor drug targeting and can be combined with local hyperthermia to trigger drug release. Although TSL-mediated drug delivery can be effective by itself, we developed doxorubicin (DOX)-containing CO2 bubble-generating TSL (TSL-C) that were found to enhance the antitumor effects of DOX owing to the synergism between burst release of drug and hyperthermia-induced CO2 generation. An ultrasound imaging system was used to monitor hyperthermia-induced CO2 generation in TSL-C and the results revealed that hyperthermia-induced CO2 generation in TSL-C led to increased DOX release compared to that observed for non-CO2-generating TSL. Moreover, TSL-C significantly inhibited the tumor growth in MDA-MB-231 tumor-bearing mice compared to TSL (p<0.004). Taken together, we demonstrated that the TSL-C platform increased the therapeutic efficacy of cancer chemotherapy and showed the applicability of this approach to increase drug release within the tumor microenvironment. As a novel and highly effective drug delivery platform, TSL-C has great potential for use in a broad range of applications for the treatment of various human diseases. We have developed a novel method for drug release from liposomes by gas (CO2) generation in tumor microenvironment. In addition, we demonstrate therapeutic efficacy in breast carcinoma. CO2-generated liposomal doxorubicin is a novel and highly attractive delivery system for anticancer drug with the potential for broad applications in human disease.

1 January 2020 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
SLSeung Taek Lim
Seung Taek Lim
YJYe Won Jeon
Ye Won Jeon
HGHongki Gwak
Hongki Gwak
YSYoung Jin Suh
Young Jin Suh
Lim ST, et al. J Breast Cancer. 2020 Oct;23(5):498-508. https://doi.org/10.4048/jbc.2020.23.e58

20 October 2013 in Journal of the Korean Chemical Society
Verified
Journal Article
Closed access
TWTae In Wee
Tae In Wee
YJYe Won Jeon
Ye Won Jeon
YCYoung Jae Cho
Young Jae Cho
SCSung Keun Cho
Sung Keun Cho
JHJeung Ha
Jeung Ha
BSByung Cheol Shin
Byung Cheol Shin

20 December 2014 in Journal of the Korean Chemical Society
Verified
Journal Article
Open access
YJYe Won Jeon
Ye Won Jeon
SCSun Hang Cho
Sun Hang Cho
HHHee Dong Han
Hee Dong Han
BSByung Cheol Shin
Byung Cheol Shin

22 March 2021 in Journal of the Korean Society of Radiology
Verified
Journal Article
Open access
PDF file
HAHyun Soo Ahn
Hyun Soo Ahn
YAYeong Yi An
Yeong Yi An
YJYe Won Jeon
Ye Won Jeon
YSYoung Jin Suh
Young Jin Suh
HCHyun Joo Choi
Hyun Joo Choi
안현수, et al. J Korean Soc Radiol. 2021 Mar;82:e52. https://doi.org/10.3348/jksr.2020.0120